Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trialSara A. Hurvitz, Javier Cortés, Joanne Wing Yan Chiu et al.|The Lancet|2022Cited by 664
Bilobol inhibits the lipopolysaccharide-induced expression and distribution of RhoA in HepG2 human hepatocellular carcinoma cellsJin Xu, Min Chen, Yueying Li et al.|Oncology Letters|2015Cited by 6
Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinasesYoung E. Whang, H. Shelton Earp, Z. Zhang et al.|UNC Libraries|2020Cited by 4